Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.

By A. Mitchell, Melissa K Y Chan, H. Bhatti, M. Halton, L. Grassi, C. Johansen, N. Meader. The Lancet Oncology, 2011

2,180 citations recorded by the source corpus.

Subfields: Oncology, Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/7448b24c9a1baa56ef83271991cc1edac8cb4ac6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pediatrics, Perinatology and Child Health

In Public Health, Environmental and Occupational Health

Citations in the corpus

Health theory of coping (2020, background): “Unpleasant emotions and psychological distress are key components of all mental illnesses (American Psychiatric Association, 2013) and many physical illnesses or the treatments of illnesses (e.g., Mitchell et al., 2011).”
Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments (2013, methodology): “[9] conducted a meta-analysis on 66 studies to determine the prevalence of depression in cancer patients in oncological, hematological and palliative care settings.”
Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies (2019, background): “Importantly, depression and anxiety are much more prevalent among cancer patients, affecting up to 20% and 10% of cancer patients, respectively [9].”
Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. (2014, background): “4% for any adjustment disorder.(64) By comparison, the National Institute of Mental Health reports 12-month prevalence estimates as being 9.”
A systematic review of reviews on the prevalence of anxiety disorders in adult populations (2016, background): “Compared to healthy populations or control groups, prevalence was higher in individuals with chronic physical diseases (Mitchell et al. 2013; Yang et al. 2013), and the burden was particularly high in the end stage (Solano et al. 2006; Murtagh et al. 2007; Mitchell et al. 2011).”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “Cancer patients often develop a chronic, clinically significant syndrome of psychosocial distress having depressed mood, anxiety, and reduced quality of life as core features, with up to 40% of cancer patients meeting criteria for a mood disorder (Holland et al., 2013; Mitchell et al., 2011).”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “Enduring clinically significant anxiety and/or depressive symptoms are common in patients with cancer, present in 30–40% of patients in hospital settings (Mitchell et al., 2011).”
Cancer treatment and survivorship statistics, 2012 (2012, background): “A recent meta-analysis found that 30% to 40% of cancer patients had diagnosable mood disorders.(91) The early detection and treatment of distress can improve treatment adherence and patient-provider communication and decrease the risk of severe depression or anxiety.”